In a Danish pilot trial (54) of six patients with metastatic melanoma treated with TILs, low-dose IL-2 (200,000 IU/kg for 14 days) considerably decreased the treatment-related toxicity, with no grade 3 to 4 IL-2-related AEs reported. This evidence concerns the gene IL2 and metastatic melanoma.